Advertisement


Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Lymphoma

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Advertisement